^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | podentamig (MK-4002) (CD3 agonist, BCMA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HARPOON THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR HPN217
Published date:
03/02/2022
Excerpt:
Harpoon Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC®, for the treatment of patients with relapsed, refractory multiple myeloma (RRMM) who have received at least four lines of therapy.
